Mid-Day Market Update: Crude Oil Falls Over 1%; Helbiz Shares Spike Higher
Midway through trading Friday, the Dow traded down 0.51% to 34,572.50 while the NASDAQ fell 0.78% to 15,062.99. The S&P also fell, dropping 0.72% to 4,441.64.
25 Stocks Moving In Friday’s Mid-Day Session
Gainers
Helbiz, Inc. (NASDAQ: HLBZ) shares jumped 92.7% to $17.35 after the company announced its media unit has entered into an agreement with FOX Networks to broadcast the Italian Serie B championship across the USA and the Caribbean.
Mid-Morning Market Update: Markets Down; US Consumer Sentiment Edges Higher
Following the market opening Friday, the Dow traded down 0.37% to 34,622.25 while the NASDAQ fell 0.58% to 15,094.19. The S&P also fell, dropping 0.55% to 4,449.03.
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera’s COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 16)
Protagonist Therapeutics Reports FDA Clinical Hold On Rusfertide Development Program
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced the receipt of a verbal communication from the U.S. Food and Drug Administration (FDA) that
The Daily Biotech Pulse: MacroGenics’ Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA’s FDA Nod
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 7)
The Daily Biotech Pulse: FDA Rejects FibroGen’s Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 10)
Protagonist Therapeutics Reports Resolution Of Contract Dispute With Zealand Pharma; Protagonist To Make $1.5M Payment To Zealand
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced it has resolved its Collaboration Agreement dispute with Zealand Pharma by reducing future development and
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $60
HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $50 to $60.